These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 12718836)

  • 21. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.
    Lim FS; Han HH; Bock HL
    Ann Acad Med Singap; 2007 Dec; 36(12):969-73. PubMed ID: 18185875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.
    Nakayama T; Kawamura A; Sogawa Y; Sakakibara S; Nakatsu T; Kimata M; Oe K
    J Infect Chemother; 2024 Dec; 30(12):1289-1294. PubMed ID: 38906375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
    Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
    Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
    Gothefors L; Bergström E; Backman M
    Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.
    Mufson MA; Diaz C; Leonardi M; Harrison CJ; Grogg S; Carbayo A; Carlo-Torres S; JeanFreau R; Quintero-Del-Rio A; Bautista G; Povey M; Da Costa C; Nicholson O; Innis BL
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):339-48. PubMed ID: 26582873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
    Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mumps, measles and rubella vaccination in children with PFAPA syndrome.
    Kraszewska-Głomba B; Matkowska-Kocjan A; Miśkiewicz K; Szymańska-Toczek Z; Wójcik M; Banyś D; Szenborn L
    Vaccine; 2016 Nov; 34(48):5903-5906. PubMed ID: 27997341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK; Chiu YL; Wilkin T
    AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
    [No Abstract]   [Full Text] [Related]  

  • 39. [Study of mumps immunity after administrating measles-mumps-rubella vaccine among children aged 2-7 years old in Jiangsu Province in 2015].
    Liu YB; Hu Y; Deng XY; Wang ZG; Sun X; Lu PS; Guo HX; Tang FY; Zhou MH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):593-597. PubMed ID: 28693082
    [No Abstract]   [Full Text] [Related]  

  • 40. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Group
    Hum Vaccin Immunother; 2019; 15(4):786-799. PubMed ID: 30785357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.